Ovoca Bio | OVG - Selling And Administration Expenses


Ovoca Bio reported EUR617K in Selling and Administration Expenses for its fiscal semester ending in December of 2025.





Selling And Administration Expenses Change Date
Akebia Therapeutics USD 23.53M 3.19M Dec/2025
Alaunos Therapeutics USD 424K 23K Jun/2026
ALKERMES USD 190.54M 6.1M Sep/2026
Avita Medical AUD 19.54M 516K Jun/2026
Dianthus Therapeutics USD 13.56M 1.09M Jun/2026
Great Western Mining Corporation EUR 595.79K 109.22K Dec/2025
Ionis Pharmaceuticals USD 154M 23.92M Sep/2026
IQVIA Holdings USD 569M 5M Sep/2026
Malin Corporation EUR 1.1M 400K Dec/2024
Moderna USD 282M 66M Sep/2026
Organon & Co USD 407M 27M Sep/2026
Ovoca Bio EUR 617K 15K Dec/2025
Revvity USD 275.33M 3.25M Sep/2026
Tectonic Therapeutic USD 6.17M 260K Jun/2026
Viatris USD 950.8M 183.7M Sep/2026
Xeris Pharmaceuticals USD 61.04M 7.89M Jun/2026